PD-1抑制剂联合来那度胺治疗复发CD5^(+)弥漫大B细胞淋巴瘤临床分析  

Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5^(+)Diffuse Large B-Cell Lymphoma

作　　者：王亚萍 张学亚[1] WANG Ya-Ping;ZHANG Xue-Ya(Department of Hematology,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,Fujian Province,China)

机构地区：[1]福建医科大学附属第二医院血液科,福建泉州362000

出　　处：《中国实验血液学杂志》2024年第4期1112-1116,共5页Journal of Experimental Hematology

摘　　要：目的:探讨复发CD5^(+)弥漫大B细胞淋巴瘤的临床特征及治疗方法。方法:收集1例CD5^(+)弥漫大B细胞淋巴瘤患者的资料,分析其临床特征、治疗转归。结果:患者合并噬血细胞综合征,经6周期R-ECHOP方案化疗达完全缓解后复发,给予PD-1抑制剂联合来那度胺治疗2周期再次达完全缓解,伴随着白介素-10表达水平下降。患者前后共化疗15个周期,病情持续处于完全缓解状态,缓解时间达24个月,白介素-10的水平持续处于正常范围。结论:PD-1抑制剂联合来那度胺方案有望成为治疗复发CD5^(+)弥漫大B细胞淋巴瘤新方案。Objective:To investigate the clinical characteristics and treatment of relapsed CD5^(+)diffuse large B-cell lymphoma(DLBCL).Methods:The data of a patient with CD5^(+)DLBCL was collected,and its clinical characteristics and treatment outcome were analyzed.Results:The patient developed hemophagocytic syndrome and achieved complete remission(CR)after 6 cycles of R-ECHOP chemotherapy,then relapsed.After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment,the patient achieved CR again accompanied by a decrease of interleukin(IL)-10 expression level.After a total of 15 cycles of chemotherapy,the patient remained in CR for 24 months,and the level of IL-10 remained in the normal range.Conclusion:PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5^(+)DLBCL.

关 键 词：PD-1抑制剂 来那度胺 CD5+弥漫大B细胞淋巴瘤 白介素-10 

分 类 号：R733.1[医药卫生—肿瘤]